Author:
Yu Rosie Z,Grundy John S,Henry Scott P,Kim Tae-Won,Norris Daniel A,Burkey Jennifer,Wang Yanfeng,Vick Andrew,Geary Richard S
Subject
Drug Discovery,Molecular Medicine
Reference20 articles.
1. Phase I trial of ISIS 104838, a 2’-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha;Sewell;J Pharmacol Exp Ther,2002
2. Synovial Biomarker Study of ISIS 104838, An Antisense Oligodeoxynucleotide Targeting TNF-alpha, in Rheumatoid Arthritis. 67th Annual Meeting of the American College of Rheumatology (ACR): Orlando, FL;Wei,2003
3. New Targets for Glycemic Control Protein-Tyrosine-Phosphatase-1B Antisense Inhibitor. the American Diabetes Association's 65th Annual Meeting: San Diego, CA;Kjems,2005
4. mRNA as a therapeutic target in lung disease;Jones;Drug Des Rev,2005
5. A phase I study of OGX-011, a 2’-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer;Chi;Clin Cancer Res,2008
Cited by
42 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献